[1] ROTRUCK J T, POPE A L, GANTHER H E, et al. Selenium: biochemical role as a component of glutathione peroxidase[J]. Science, 1973, 179(4073):588-590. doi:  10.1126/science.179.4073.588
[2] STEINBRENNER H, SIES H. Protection against reactive oxygen species by selenoproteins[J]. Biochim Biophys Acta BBA Gen Subj, 2009, 1790(11):1478-1485. doi:  10.1016/j.bbagen.2009.02.014
[3] MÜLLER A, CADENAS E, GRAF P, et al. A novel biologically active seleno-organic compound—1[J]. Biochem Pharmacol, 1984, 33(20):3235-3239. doi:  10.1016/0006-2952(84)90083-2
[4] BHOWMICK D, MUGESH G. Insights into the catalytic mechanism of synthetic glutathione peroxidase mimetics[J]. Org Biomol Chem, 2015, 13(41):10262-10272. doi:  10.1039/C5OB01665G
[5] GUL S, BAHADIR B, HANCI V, et al. Effects of ebselen versus nimodipine on cerebral vasospasm subsequent to experimental subarachnoid hemorrhage in rats[J]. J Clin Neurosci, 2010, 17(5):608-611. doi:  10.1016/j.jocn.2009.07.115
[6] WATANABE T, NISHIYAMA M, HORI T, et al. Ebselen(DR3305)ameliorates delayed cerebral vasospasm in a canine two-hemorrhage model[J]. Neurol Res, 1997, 19(5):563-565. doi:  10.1080/01616412.1997.11740859
[7] YAMAGUCHI T, SANO K, TAKAKURA K, et al. Ebselen in acute ischemic stroke: a placebo-controlled, double-blind clinical trial. Ebselen Study Group[J]. Stroke, 1998, 29(1):12-17. doi:  10.1161/01.STR.29.1.12
[8] SAITO I, ASANO T, SANO K, et al. Neuroprotective effect of an antioxidant, ebselen, in patients with delayed neurological deficits after aneurysmal subarachnoid hemorrhage[J]. Neurosurgery, 1998, 42(2):269-277. doi:  10.1097/00006123-199802000-00038
[9] RABINOWITZ P M. Noise-induced hearing loss[J]. Am Fam Physician, 2000, 61(9):2749-2756,2759-2760.
[10] DING T H, YAN A H, LIU K. What is noise-induced hearing loss?[J]. Br J Hosp Med, 2019, 80(9):525-529. doi:  10.12968/hmed.2019.80.9.525
[11] KIL J, HARRUFF E E, LONGENECKER R J. Development of ebselen for the treatment of sensorineural hearing loss and tinnitus[J]. Hear Res, 2022, 413:108209. doi:  10.1016/j.heares.2021.108209
[12] COWEN P J. Backing into the future: pharmacological approaches to the management of resistant depression[J]. Psychol Med, 2017, 47(15):2569-2577. doi:  10.1017/S003329171700068X
[13] DEL MATTO L, MUSCAS M, MURRU A, et al. Lithium and suicide prevention in mood disorders and in the general population: a systematic review[J]. Neurosci Biobehav Rev, 2020, 116:142-153. doi:  10.1016/j.neubiorev.2020.06.017
[14] National Institute for Health and Clinical Excellence(NICE). Depression: Evidence Update April 2012: A summary of selected new evidence relevant to NICE clinical guideline 90 ‘The treatment and management of depression in adults’ (2009)[R]. London: National Institute for Health and Clinical Excellence (NICE); 2012. (Evidence Update, No. 13. ) Available from: https://www.ncbi.nlm.nih.gov/books/NBK552056/.
[15] MCKNIGHT R F, ADIDA M, BUDGE K, et al. Lithium toxicity profile: a systematic review and meta-analysis[J]. Lancet, 2012, 379(9817):721-728. doi:  10.1016/S0140-6736(11)61516-X
[16] ANTONIADOU I, KOUSKOU M, ARSIWALA T, et al. Ebselen has lithium-like effects on central 5-HT2A receptor function[J]. Br J Pharmacol, 2018, 175(13):2599-2610. doi:  10.1111/bph.14179
[17] BERRIDGE M J, DOWNES C P, HANLEY M R. Neural and developmental actions of lithium: a unifying hypothesis[J]. Cell, 1989, 59(3):411-419. doi:  10.1016/0092-8674(89)90026-3
[18] HARWOOD A J. Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited[J]. Mol Psychiatry, 2005, 10(1):117-126. doi:  10.1038/sj.mp.4001618
[19] BARKUS C, FERLAND J M N, ADAMS W K, et al. The putative lithium-mimetic ebselen reduces impulsivity in rodent models[J]. J Psychopharmacol Oxf Engl, 2018, 32(9):1018-1026. doi:  10.1177/0269881118784876
[20] TRIPATHI N, TRIPATHI N, GOSHISHT M K. COVID-19: inflammatory responses, structure-based drug design and potential therapeutics[J]. Mol Divers, 2022, 26(1):629-645. doi:  10.1007/s11030-020-10176-1
[21] JIN Z M, DU X Y, XU Y C, et al. Structure of mpro from SARS-CoV-2 and discovery of its inhibitors[J]. Nature, 2020, 582(7811):289-293. doi:  10.1038/s41586-020-2223-y
[22] YOUNIS W, THANGAMANI S, SELEEM M N. Repurposing non-antimicrobial drugs and clinical molecules to treat bacterial infections[J]. Curr Pharm Des, 2015, 21(28):4106-4111. doi:  10.2174/1381612821666150506154434
[23] ABDELKHALEK A, ABUTALEB N S, MOHAMMAD H, et al. Repurposing ebselen for decolonization of vancomycin-resistant enterococci(VRE)[J]. PLoS One, 2018, 13(6):e0199710. doi:  10.1371/journal.pone.0199710
[24] ZOU L L, LU J, WANG J, et al. Synergistic antibacterial effect of silver and ebselen against multidrug-resistant Gram-negative bacterial infections[J]. EMBO Mol Med, 2017, 9(8):1165-1178. doi:  10.15252/emmm.201707661
[25] THANGAMANI S, YOUNIS W, SELEEM M N. Repurposing ebselen for treatment of multidrug-resistant staphylococcal infections[J]. Sci Rep, 2015, 5:11596. doi:  10.1038/srep11596
[26] ZHANG D W, YAN H L, XU X S, et al. The selenium-containing drug ebselen potently disrupts LEDGF/p75-HIV-1 integrase interaction by targeting LEDGF/p75[J]. J Enzyme Inhib Med Chem, 2020, 35(1):906-912. doi:  10.1080/14756366.2020.1743282
[27] MUKHERJEE S, WEINER W S, SCHROEDER C E, et al. Ebselen inhibits hepatitis C virus NS3 helicase binding to nucleic acid and prevents viral replication[J]. ACS Chem Biol, 2014, 9(10):2393-2403. doi:  10.1021/cb500512z
[28] HADDAD E B, MCCLUSKIE K, BIRRELL M A, et al. Differential effects of ebselen on neutrophil recruitment, chemokine, and inflammatory mediator expression in a rat model of lipopolysaccharide-induced pulmonary inflammation[J]. J Immunol, 2002, 169(2):974-982. doi:  10.4049/jimmunol.169.2.974
[29] SIMANJUNTAK Y, LIANG J J, CHEN S Y, et al. Ebselen alleviates testicular pathology in mice with Zika virus infection and prevents its sexual transmission[J]. PLoS Pathog, 2018, 14(2):e1006854. doi:  10.1371/journal.ppat.1006854
[30] HÜTHER A M, ZHANG Y, SAUER A, et al. Antimalarial properties of ebselen[J]. Parasitol Res, 1989, 75(5):353-360. doi:  10.1007/BF00931130
[31] LU J, VODNALA S K, GUSTAVSSON A L, et al. Ebsulfur is a benzisothiazolone cytocidal inhibitor targeting the trypanothione reductase of Trypanosoma brucei[J]. J Biol Chem, 2013, 288(38):27456-27468. doi:  10.1074/jbc.M113.495101
[32] Welter André Dr. , Christiaens Léon Dr. , Wirtz-Peitz Dr. New benzisoselenazolones, process for producing the same and pharmaceutical preparations containing the same. Europe, EP0044453[p]. 1981-07-04.
[33] NASCIMENTO V, CORDEIRO P S, ARCA M, et al. Fast and easy conversion of ortho amidoaryldiselenides into the corresponding ebselen-like derivatives driven by theoretical investigations[J]. New J Chem, 2020, 44(22):9444-9451. doi:  10.1039/D0NJ01605E
[34] ENGMAN L, HALLBERG A. Expedient synthesis of ebselen and related compounds[J]. J Org Chem, 1989, 54(12):2964-2966. doi:  10.1021/jo00273a035
[35] FONG M C, SCHIESSER C H. Reactions of 2, 2’-diselenobis (N-alkylbenzamides) with peroxides: a free-radical synthesis of Ebselen and related analogues[J]. Tetrahedron Lett, 1995, 36(40):7329-7332. doi:  10.1016/0040-4039(95)01511-F
[36] OPPENHEIMER J,. Synthesis of 2-phenyl-1, 2-benziso[77Se]selenazol-3(2H)-one: “ebselen”[J]. J Label Compd Radiopharm, 1996, 38(3):281-284. doi:  10.1002/(SICI)1099-1344(199603)38:3<281::AID-JLCR833>3.0.CO;2-1
[37] ZADE S S, PANDA S, SINGH H B, et al. Synthesis of diaryl selenides using the in situ reagent SeCl2[J]. Tetrahedron Lett, 2005, 46(4):665-669. doi:  10.1016/j.tetlet.2004.11.125
[38] SINGH V P, POON J F, YAN J J, et al. Nitro-, azo-, and amino derivatives of ebselen: synthesis, structure, and cytoprotective effects[J]. J Org Chem, 2017, 82(1):313-321. doi:  10.1021/acs.joc.6b02418
[39] BALKRISHNA S J, BHAKUNI B S, CHOPRA D, et al. Cu-catalyzed efficient synthetic methodology for ebselen and related Se–N heterocycles[J]. Org Lett, 2010, 12(23):5394-5397. doi:  10.1021/ol102027j
[40] PACUŁA A J, ŚCIANOWSKI J, ALEKSANDRZAK K B. Highly efficient synthesis and antioxidant capacity of N-substituted benzisoselenazol-3(2H)-ones[J]. RSC Adv, 2014, 4(90):48959-48962. doi:  10.1039/C4RA08631G